## Surveillance of **Tuberculosis** in Europe - **EuroTB**



WHO Collaborating Centre for the Surveillance of Tuberculosis in Europe









## Surveillance of tuberculosis in Europe: participating countries and national institutions

Ministry of Health and Welfare Andorra la Vella Andorra Ministry of Health and Environment Albania Tirana University Hospital of Lung Diseases Tirana Ministry of Health Armenia Yerevan Bundesministerium für soziale Sicherheit und Generationen Austria Vienna Azerbaijan Ministry of Health Baku Belarus Scientific Research Institute of Pneumology and Pthisiology Minsk Belgium Lung & Tuberculosis Association (BELTA) Brussels Belgium Bosnia & Herzegovina Clinic of Pulmonary Diseases and Tuberculosis "Podhrastovi" Saraievo Public Health Institute Banja Luka Bulgaria Ministry of Health Sofia Croatia Croatian National Institute of Public Health Zagreb Czech Republic Clinic of Chest Diseases & Thoracic Surgery Prague Denmark Statens Serum Institut Copenhagen Tartu University Lung Hospital Estonia Tartu Finland National Public Health Institute Helsinki Direction Générale de la Santé Paris France Institut de Veille Sanitaire Saint-Maurice Institute of Phtisiology and Pulmonology Tbilisi Georgia Germany Robert Koch-Institut Berlin National Centre for Surveillance and Intervention (NCSI) Greece Athens Hungary "Koranyi" National Institute of Tuberculosis & Pulmonology Budapest Iceland Reykjavik Health Care Centre Reykjavik National Disease Surveillance Centre Ireland Dublin Israel Ministry of Health Jerusalem Ministero della Salute Italy Roma Istituto Superiore di Sanità Roma Kazakhstan Kazakh Tuberculosis Research Institute Almaty Kyrgyzstan National Tuberculosis & Lung Diseases Institute Bishkek Latvia State Centre of Tuberculosis & Lung Diseases of Latvia Riga Lithuanian Centre of Pneumology & Tuberculosis Lithuania Vilnius Luxembourg Direction Générale de la Santé Luxembourg Macedonia, Former Institute for Lung Diseases and Tuberculosis Skopje Yugoslav Republic Department of Health G'mangia Malta Moldova, Republic of The Republican Phtisiopulmonology Clinic Chisinau Monaco Direction de l'Action Sanitaire et Sociale Monaco Netherlands Royal Netherlands Tuberculosis Association (KNCV) The Hague Norway National Health Screening Service Oslo Poland National Tuberculosis & Lung Diseases Institute Warsaw Ministério da Saúde Lisbon Portugal Institute of Pneumophtisiology "Marius Nasta" Romania Bucharest Russian Federation Russian Research Institute of Pneumophtisiology Moscow Ospedale di Stato di San Marino San Marino Cailungo Slovakia Ministry of Health Bratislava Slovenia University Institute of Diseases of the Chest Golnik Instituto de Salud "Carlos III" Spain Madrid Sweden Swedish Institute for Infectious Disease Control Solna Swiss Federal Office of Public Health Switzerland Bern Tajikistan Medical University, Department of Tuberculosis Dushanbe Tajikistan Ministry of Health Turkey Ankara Central Hospital for Tuberculosis Turkmenistan Ashkhabad Institute of Tuberculosis & Pulmonology Ukraine Kiev United Kingdom PHLS Communicable Disease Surveillance Centre London

Scottish Centre for Infection & Environmental Health

Uzbekistan

Yugoslavia

Communicable Disease Surveillance Centre, Northern Ireland

Scientific Research Institute of Pthisiology and Pulmonology

Institute of Pulmonology & Protection against Tuberculosis

Glasgow

Tashkent

Belgrade

Belfast

EuroTB is a European surveillance network set up in 1996, managed jointly by the Institut de Veille Sanitaire (InVS), France and the Royal Netherlands Tuberculosis Association (KNCV), the Netherlands and financially supported by the European Commission (DG-SANCO). EuroTB aims at improving the contribution of surveillance to tuberculosis control in the WHO European region, through the provision of valid, comparable epidemiological information on tuberculosis. EuroTB is based on the voluntary participation of the national coordinators for tuberculosis surveillance in the 51 countries of the WHO European Region.

Surveillance of tuberculosis in Europe is the annual report prepared by the EuroTB project staff with the collaboration of the members of the EuroTB Advisory Committee. Single copies and regular mailing can be requested at the address below; the report is also accessible via the website: **www.eurotb.org**.

**EuroTB staff**: Andrea Infuso, coordinator, InVS; Delphine Antoine, epidemiologist, InVS; Hedwige Bousquié, assistant, InVS; and Jaap Veen, tuberculosis consultant, KNCV.

Advisory committee: Luke Clancy (IUATLD-Europe Region), Francis Drobniewski (United Kingdom) Sven Hoffner (Sweden), Jean-Paul Klein (Austria), Annika Krüüner (Estonia), Kitty Lambregts (Netherlands), Maria-Luisa Moro (Italy), Mario Raviglione (WHO-HQ), Hans Rieder (IUATLD), Victoria Romanus (Sweden), Petri Ruutu (Finland), Jurij Sorli (Slovenia), John Watson (United Kingdom), Richard Zaleskis (WHO-Regional Office for Europe).

## Suggested citation:

EuroTB (InVS/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European Region.

Surveillance of tuberculosis in Europe.

Report on tuberculosis cases notified in 1999,

March 2002

Neither the European Commission nor any person acting on behalf of the commission is liable for the use that may be made of the information contained in this report.

## **TABLE OF CONTENTS**

1	Sum	mary	7
	1.1 1.2 1.3	English French Russian (резюме на русском языке)	7 9 11
	1.5	nussian (pesione na pycchom asbike)	11
2	Tech	nical note	13
	2.1 2.2	Data collection Definitions Data presentation	13 13 15
	2.0	Data presentation	13
3	Char	acteristics of national TB case notification systems	17
	3.1	Sources of case notification	17
	3.2 3.3	Bacteriological diagnosis of TB Case classification	17 17
	3.4	Completeness of TB notifications	17
4	Tube	erculosis cases notified in 1999	19
	4.1	Information provided	19
	4.2 4.3	Global figures and trends Sex and age	19 21
	4.4	Geographic origin	22
		Previous anti-tuberculosis treatment Site of disease	24 24
	4.7	Bacteriology results	24
		4.7.1 Culture 4.7.2 Species identification	24 25
		4.7.3 Sputum smear	25
5	Drug	resistance surveillance in 1999	27
		Laboratory practices	27
	5.2 5.3	Source of data Results	27 27
		<ul><li>5.3.1 Countries providing representative national data (group A)</li><li>5.3.2 Countries providing other data (group B)</li></ul>	28 29
6	Refe	rences	31
TA	BLES		
Та	ble 1	Sources of TB notifications and inclusion of cases diagnosed in specific populations, 1999	34
Ta	ble 2	Tuberculosis surveillance data provided to EuroTB, 1999	35
Ta	ble 3	Total number of tuberculosis cases notified and rates per 100 000 population, 1995-1999	36
Ta	ble 4	Tuberculosis cases by sex, 1999	37
Ta	ble 5	Tuberculosis cases by age group, 1999	38
Та	ble 6	Tuberculosis cases by geographic origin, 1999	40

Table 7	Foreign tuberculosis cases by continent of origin, 1999	41
Table 8	Tuberculosis cases by previous anti-TB treatment status, 1999	42
Table 9	Tuberculosis cases by site of disease, 1999	43
Table 10	Sites of disease among tuberculosis cases, by age group, 1999	44
Table 11	Tuberculosis cases by culture result, 1999	45
Table 12	Tuberculosis cases by culture result and site of disease, 1999	46
Table 13	Tuberculosis cases by M. tuberculosis complex species, 1999	47
Table 14	Pulmonary / respiratory tuberculosis cases by sputum smear result, 1999	48
Table 15	Laboratory practices for drug susceptibility testing (DST), 1999	49
Table 16	Characteristics of drug resistance surveillance, 1999	50
Table 17	Global drug resistance at the start of treatment, tuberculosis cases, 1999	51
Table 18	Drug resistance at the start of treatment, tuberculosis cases never treated with anti-TB drugs, 1999	52
Table 19	Drug resistance at the start of treatment, tuberculosis cases previously treated with anti-TB drugs, 1999	53
Table 20	Drug resistance at the start of treatment, tuberculosis cases born in the country / national citizens, 1999	54
Table 21	Drug resistance at the start of treatment, tuberculosis cases born abroad / foreign citizens, 1999	55
	abioad / loreign chizeris, 1999	
FIGURES A		
	AND MAPS	20
Figure 1	AND MAPS  Tuberculosis notification rates by geographic area, 1995-1999	20
Figure 1 Figure 2	AND MAPS  Tuberculosis notification rates by geographic area, 1995-1999  Notification rates by age group and sex, 1999	21
Figure 1 Figure 2 Figure 3	Tuberculosis notification rates by geographic area, 1995-1999  Notification rates by age group and sex, 1999  TB notification rates by age group, sex and geographic origin, 1999, West	21
Figure 1 Figure 2 Figure 3 Figure 4	Tuberculosis notification rates by geographic area, 1995-1999  Notification rates by age group and sex, 1999  TB notification rates by age group, sex and geographic origin, 1999, West  Tuberculosis cases by geographic origin, 1995-1999, West	21 23 23
Figure 1 Figure 2 Figure 3	Tuberculosis notification rates by geographic area, 1995-1999  Notification rates by age group and sex, 1999  TB notification rates by age group, sex and geographic origin, 1999, West	21
Figure 1 Figure 2 Figure 3 Figure 4	Tuberculosis notification rates by geographic area, 1995-1999  Notification rates by age group and sex, 1999  TB notification rates by age group, sex and geographic origin, 1999, West  Tuberculosis cases by geographic origin, 1995-1999, West	21 23 23
Figure 1 Figure 2 Figure 3 Figure 4 Figure 5	Tuberculosis notification rates by geographic area, 1995-1999  Notification rates by age group and sex, 1999  TB notification rates by age group, sex and geographic origin, 1999, West  Tuberculosis cases by geographic origin, 1995-1999, West  Proportion of multidrug resistant TB cases by previous anti-TB treatment status, 1999	21 23 23 28
Figure 1 Figure 2 Figure 3 Figure 4 Figure 5	Tuberculosis notification rates by geographic area, 1995-1999  Notification rates by age group and sex, 1999  TB notification rates by age group, sex and geographic origin, 1999, West  Tuberculosis cases by geographic origin, 1995-1999, West  Proportion of multidrug resistant TB cases by previous anti-TB treatment status, 1999  Tuberculosis notification rates per 100 000 population, 1999	21 23 23 28
Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Map 1 Map 2	Tuberculosis notification rates by geographic area, 1995-1999  Notification rates by age group and sex, 1999  TB notification rates by age group, sex and geographic origin, 1999, West  Tuberculosis cases by geographic origin, 1995-1999, West  Proportion of multidrug resistant TB cases by previous anti-TB treatment status, 1999  Tuberculosis notification rates per 100 000 population, 1999  Average annual change in TB notification rates, 1995-1999  Proportion of TB cases of foreign origin, 1999	21 23 23 28
Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Map 1 Map 2 Map 3	Tuberculosis notification rates by geographic area, 1995-1999  Notification rates by age group and sex, 1999  TB notification rates by age group, sex and geographic origin, 1999, West  Tuberculosis cases by geographic origin, 1995-1999, West  Proportion of multidrug resistant TB cases by previous anti-TB treatment status, 1999  Tuberculosis notification rates per 100 000 population, 1999  Average annual change in TB notification rates, 1995-1999  Proportion of TB cases of foreign origin, 1999	21 23 23 28
Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Map 1 Map 2 Map 3 COUNTRY	Tuberculosis notification rates by geographic area, 1995-1999  Notification rates by age group and sex, 1999  TB notification rates by age group, sex and geographic origin, 1999, West  Tuberculosis cases by geographic origin, 1995-1999, West  Proportion of multidrug resistant TB cases by previous anti-TB treatment status, 1999  Tuberculosis notification rates per 100 000 population, 1999  Average annual change in TB notification rates, 1995-1999  Proportion of TB cases of foreign origin, 1999	21 23 23 28 19 20 23